Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF.

@article{Koski2010TreatmentOC,
  title={Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF.},
  author={Anniina Koski and Lotta Kangasniemi and Sophie Escutenaire and Sari Pesonen and Vincenzo Cerullo and Iulia Diaconu and Petri Nokisalmi and Mari Raki and Maria Rajecki and Kilian Guse and Tuuli Ranki and Minna Oksanen and Sirkka-Liisa Holm and Elina Haavisto and Aila Karioja-Kallio and Leena Laasonen and Kaarina P L Partanen and Matteo Ugolini and Andreas Helminen and Eerika Karli and P{\"a}ivi Hannuksela and Saila K. Pesonen and Timo K Joensuu and Anna Kanerva and Akseli Hemminki},
  journal={Molecular therapy : the journal of the American Society of Gene Therapy},
  year={2010},
  volume={18 10},
  pages={1874-84}
}
Augmenting antitumor immunity is a promising way to enhance the potency of oncolytic adenoviral therapy. Granulocyte-macrophage colony-stimulating factor (GMCSF) can mediate antitumor effects by recruiting natural killer cells and by induction of tumor-specific CD8(+) cytotoxic T-lymphocytes. Serotype 5 adenoviruses (Ad5) are commonly used in cancer gene therapy. However, expression of the coxsackie-adenovirus receptor is variable in many advanced tumors and preclinical data have demonstrated… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 100 extracted citations

Similar Papers

Loading similar papers…